Abstract:e15059 Background: Hyperpolarized 13C (HP 13C) MRI is a novel molecular imaging approach that detects aberrant aerobic metabolism, namely elevated rates of pyruvate-to-lactate conversion (kPL), in patients with advanced malignancies. Higher kPL has been shown to correlate with higher tumor grade among patients with localized prostate cancer (PC). This research sought to evaluate the correlation between kPL and clinical outcome measures in patients with advanced PC. Methods: Patients with metastatic or locally advanced PC (castration sensitive or resistant) were prospectively enrolled at our institution and underwent HP 13C MRI of one or more target lesions identified on prior conventional imaging. Voxelwise kPL values were computed in MATLAB using an inputless two site exchange model. kPL,median was defined as the median kPL value per-patient across all target lesions; kPL,kurtosis measured the tailedness of the kPL distribution per-patient. We retrospectively analyzed progression free survival (PFS) and overall survival (OS) in subgroups divided by metabolic activity below versus above cut-point (kPL,median <0.017 s-1 and ≥ 0.017s-1, respectively). Survival statistics were calculated using the Cox PH model. Results: Sixteen patients (6 with castration-sensitive and 10 with castration-resistant PC) were accrued. With a median follow-up of 22.0 months from the date of MRI, the lower-kPL subgroup had significantly longer median PFS (11.2 vs 0.5 months; p<0.01) and OS (NR vs 18.4 months; p<0.05) compared to the higher-kPL subgroup. By comparison, baseline serum PSA (PFS: p=0.19, OS: p=0.41) and LDH (PFS: p=0.60, OS: p=0.34) did not demonstrate a significant association with clinical outcomes. There was a strong negative correlation between kPL,kurtosis and OS (r = -0.75), and moderate negative correlations between kPL,median and OS (r = -0.45) as well as kPL,max with both PFS (r = -0.48) and OS (r = -0.54). There was no significant kPL,median difference between castration-sensitive and resistant subgroups (0.015±0.011 vs 0.016±0.006 s-1, p>0.8). Conclusions: HP 13C MRI-derived non-invasive metabolic biomarker kPL,median significantly correlated with clinical outcome measures in a retrospective analysis of patients with advanced PC, outperforming established serological prognostic markers PSA and LDH. Limitations include our small sample size, retrospective design, and heterogeneous patient population. Nevertheless, these encouraging preliminary results support further investigation of HP 13C MRI as a prognostic and/or predictive PC biomarker in multi-center prospective imaging trials. [Table: see text]

Specialized Computational Methods for Denoising, B1 Correction, and Kinetic Modeling in Hyperpolarized 13 C MR EPSI Studies of Liver Tumors.

Hyperpolarized 13C metabolic imaging of the human abdomen with spatiotemporal denoising

Hyperpolarized 13 C Metabolic Imaging of the Human Abdomen with Spatiotemporal Denoising.

Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients

Integrative Hyperpolarized 13C Metabolic and Standard-of-Care Abdominopelvic Staging/Restaging MRI for Patients with Advanced Solid Tumors

Improving Multiparametric MR‐transrectal Ultrasound Guided Fusion Prostate Biopsies with Hyperpolarized 13C Pyruvate Metabolic Imaging: A Technical Development Study

Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study

A pharmacokinetic model for hyperpolarized 13C‐pyruvate MRI when using metabolite‐specific bSSFP sequences

Mutual-Information Based Optimal Experimental Design for Hyperpolarized $^{13}$C-Pyruvate MRI

Advanced Hyperpolarized 13C Metabolic Imaging Protocol for Patients with Gliomas: A Comprehensive Multimodal MRI Approach

Current methods for hyperpolarized [1‐13C]pyruvate MRI human studies

Non-Invasive Assessment of Lactate Production and Compartmentalization in Renal Cell Carcinomas Using Hyperpolarized 13C Pyruvate MRI

Current Methods for Hyperpolarized [1-13C]pyruvate MRI Human Studies

Hyperpolarized C-13 Mri: State Of The Art And Future Directions

Correlating Survival Outcomes in Patients with Advanced Prostate Cancer with Novel Hyperpolarized 13C MRI Metabolic Imaging Biomarkers.

Hyperpolarized C MRI: State of the Art and Future Directions.

Characterizing Metabolic Heterogeneity of Hepatocellular Carcinoma with Hyperpolarized 13C Pyruvate MRI and Mass Spectrometry

In Vivo Molecular Imaging of Breast Cancer Metabolic Heterogeneity Using [1-13C]Pyruvate-d3 Hyperpolarized By Reversible Exchange With Parahydrogen

Metabolic Reprogramming and Validation of Hyperpolarized 13C Lactate As a Prostate Cancer Biomarker Using a Human Prostate Tissue Slice Culture Bioreactor.

Enhancing Cancer Diagnosis with Real-Time Feedback: Tumor Metabolism through Hyperpolarized 1-13C Pyruvate MRSI

Mapping Pyruvate-to-Lactate Rate Constants in Hyperpolarized Data with Bssfp Acquisitions